Loading
MI
MaxCyte Inc. Stock: price and insider trades · United Kingdom
MaxCyte Inc.: what insiders have been doing
Insider filings for MaxCyte Inc. are scarce in the RNS (LSE) feed, the latest one published on 31 January 2024. This page will fill in as new trades are disclosed. These figures are compiled from regulatory filings published by RNS (LSE). They describe what insiders did and are not a recommendation.
Insider Decl.
2
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€301
1 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
Last declaration on 31 January 2024
Declarations2 total
5,000 shares@ £0.021429.4% of flowUS Stock Exchange, NasdaqRNS:5050357-0
5,000 shares@ £0.051570.6% of flowUS Stock Exchange, NasdaqRNS:5050357-1
2 of 2 declarations
About MaxCyte Inc.
MaxCyte Inc. is a company specializing in gene and cell transfer technologies. It develops solutions for research and cell therapy.
